首頁 > 市場調查報告書 > 醫療設備

心血管設備

市場調查報告書

商品編碼

1510442

心臟幫浦設備市場規模 - 按類型（植入式、體外）、設備（心室輔助設備、全人工心臟、主動脈內球囊幫浦、體外膜氧合）、治療、最終用途和預測，2024 - 2032 年

Heart Pump Device Market Size - By Type (Implanted, Extracorporeal), Device (Ventricular Assist Devices, Total Artificial Hearts, Intra-Aortic Balloon Pumps, Extracorporeal Membrane Oxygenation), Therapy, End-use & Forecast, 2024 - 2032

出版日期: 2024年04月01日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在全球心血管疾病盛行率上升的推動下，2024 年至 2032 年間，心泵設備市場規模的複合年成長率將達到 17.4%。根據英國心臟基金會的統計，估計有 2 億人患有心血管疾病。近年來，心臟衰竭、冠狀動脈疾病和心肌病變等疾病已成為心臟泵設備需求不斷成長的主要原因。此外，人口老化的加劇以及不健康生活方式和肥胖的增加正在增加心血管疾病的風險，有利於產品需求。

與心臟幫浦裝置相關的微創手術，包括更短的恢復時間、更低的併發症風險和更好的患者治療結果，有助於提高醫療保健提供者和患者的接受度。主要市場參與者的策略性舉措，包括產品創新、策略合作和擴大產品組合的收購，也刺激了市場成長。

整個產業分為類型、設備、治療、最終用途和地區。

根據治療，預計到2032 年，從過渡到恢復(BTR) 治療領域的心臟泵設備市場複合年成長率將達到16%，這得益於其為等待心臟移植或康復的嚴重心臟衰竭患者提供的臨時循環支援。對於不適合緊急心臟移植並需要額外支持以幫助心臟從急性心臟病發作中恢復的患者來說，這種療法是救星。用於心肺復甦術的心臟幫浦裝置，例如心室輔助裝置 (VAD)，也提供機械循環支持，以改善心臟功能，讓患者在等待進一步治療時穩定並恢復體力。

由於為終末期心臟衰竭患者提供全面解決方案的需求不斷成長，預計 2024 年至 2032 年，整個人工心臟 (TAH) 領域的心臟泵設備市場將產生高收入，複合年成長率為 21.7%。全心臟被設計為移植的橋樑或作為不適合移植的患者的永久解決方案。設備技術的快速進步，包括提高生物相容性、耐用性、尺寸更小以改善患者治療效果以及擴大相關患者群體，有利於該細分市場的成長。

2024年至2032年，亞太地區心泵設備產業規模將以18.8%的複合年成長率快速擴張。快速的城市化和工業化增加了與生活方式相關的風險因素，從而提高了該地區心血管疾病的發生率。中國、印度和日本等國家醫療保健基礎設施的進步、收入的增加和醫療保健支出的增加，透過改善患者獲得先進心臟治療（包括心泵設備）的機會來推動市場成長。

產業生態系統分析
產業影響力
- 成長動力
  - 心臟衰竭和心血管疾病的數量增加
  - 技術進步
  - 提高對心臟衰竭治療的認知
  - 研發支出不斷成長
- 產業陷阱與挑戰
  - 嚴格的監管場景
  - 設備和流程成本高
成長潛力分析
波特的分析
PESTEL分析
未來市場趨勢
報銷場景
監管環境
技術景觀
缺口分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
植入式心臟幫浦裝置
體外心臟幫浦裝置

第 6 章：市場估計與預測：按設備分類，2021 - 2032 年

主要趨勢
心室輔助裝置 (VAD)
- 左心室輔助裝置 (LVAD)
- 右心室輔助裝置 (RVAD)
- 雙心室輔助裝置 (BiVAD)
- 經皮心室輔助裝置 (PVAD)
全人工心臟 (TAH)
主動脈內球囊反搏幫浦 (IABP)
體外膜氧合（ECMO）

第 7 章：市場估計與預測：按治療方式，2021 - 2032 年

主要趨勢
目的地治療
候選過渡 (BTC) 療法
移植橋 (BTT) 療法
復健過渡 (BTR) 療法
其他療法

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
心臟中心
門診手術中心
其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Abbott Laboratories
ABIOMED
Berlin Heart
BiVACOR Inc.
CARMAT
CorWave SA
Evaheart, Inc.
Fresenius SE & Co. KGaA
Getinge AB
Jarvik Heart
Leviticus Cardio
LivaNova PLC
Medtronic plc
SynCardia Systems, LLC
Teleflex Incorporated

簡介目錄

Product Code: 8787

Heart pump device market size will register 17.4% CAGR between 2024 and 2032, driven by rising prevalence of cardiovascular diseases worldwide. As per British Heart Foundation, an estimated 200 million people suffer from cardiovascular disorders. Of late, diseases, such as heart failure, coronary artery disease, and cardiomyopathy have become the major reasons for the growing demand for heart pump devices. Moreover, the growing aging population along with the rising unhealthy lifestyles and obesity are increasing the risk of cardiovascular diseases, favoring the product demand.

Minimally invasive procedures associated with heart pumping devices, including shorter recovery times, lower risk of complications, and better patient outcomes are contributing to their increased acceptance among healthcare providers and patients. Strategic initiatives by key market players including product innovations, strategic collaborations, and acquisitions for expanding product portfolios is also stimulating the market growth.

The overall industry is segmented into type, device, therapy, end-use and region.

Based on therapy, the heart pump device market from the bridge to recovery (BTR) therapy segment is anticipated to witness 16% CAGR through 2032, backed by its temporary circulatory support to patients with severe heart failure while awaiting heart transplantation or recovery. This therapy is a lifesaver for patients who are not eligible for an urgent heart transplant and need extra support to help their heart recover from an acute heart attack. Heart pumping devices used in cardiopulmonary resuscitation, such as ventricular assist devices (VADs) also provide mechanical circulatory support to improve heart function and allow patients to stabilize and regain strength while awaiting further treatment.

Heart pump device market from the total artificial hearts (TAH) segment is estimated to generate high revenue at 21.7% CAGR from 2024 to 2032, favored by the rising need for offering a comprehensive solution for patients with end-stage heart failure. Total hearts are designed as a bridge to transplantation or as a permanent solution for patients who are not transplant candidates. Rapid advancements in device technology, including improved biocompatibility, durability, smaller for better patient outcomes and expanding relevant patient populations is favoring the segment growth.

Asia Pacific heart pump device industry size will witness rapid expansion at 18.8% CAGR between 2024-2032. The rapid urbanization and industrialization are contributing to lifestyle-related risk factors, elevating the incidence of CVDs in the region. Advancements in healthcare infrastructure, rising incomes, and healthcare spending in countries, such as China, India, and Japan are driving market growth by improving patient access to advanced cardiac treatments, including heart pump devices.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in number of heart failures and cardiovascular diseases
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Rise in awareness regarding heart failure treatment
  - 3.2.1.4 Growing R&D expenditure
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory scenario
  - 3.2.2.2 High cost of device and procedures
3.3 Growth potential analysis
3.4 Porter's analysis
3.5 PESTEL analysis
3.6 Future market trends
3.7 Reimbursement scenario
3.8 Regulatory landscape
3.9 Technological landscape
3.10 GAP analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Implanted heart pump devices
5.3 Extracorporeal heart pump devices

Chapter 6 Market Estimates and Forecast, By Device, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Ventricular assist devices (VADs)
- 6.2.1 Left ventricular assist devices (LVAD)
- 6.2.2 Right ventricular assist devices (RVAD)
- 6.2.3 Bi-ventricular assist devices (BiVAD)
- 6.2.4 Percutaneous ventricular assist devices (PVAD)
6.3 Total artificial hearts (TAHs)
6.4 Intra-aortic balloon pumps (IABPs)
6.5 Extracorporeal membrane oxygenation (ECMO)

Chapter 7 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Destination therapy
7.3 Bridge-to-candidacy (BTC) therapy
7.4 Bridge-to-transplant (BTT) therapy
7.5 Bridge-to-recovery (BTR) therapy
7.6 Other therapies

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Cardiac centers
8.4 Ambulatory surgical centers
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa